BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer

  • Kim, Dong Hyun (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Kim, Hye-Min (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Huong, Pham Thi Thu (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Han, Ho-Jin (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Hwang, Joonsung (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Cha-Molstad, Hyunjoo (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Lee, Kyung Ho (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Ryoo, In-Ja (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Kim, Kyoon Eon (Department of Biochemistry, College of Natural Science, Chungnam National University) ;
  • Huh, Yang Hoon (Center for Electron Microscopy Research, Korea Basic Science Institute) ;
  • Ahn, Jong Seog (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Kwon, Yong Tae (Protein Metabolism Medical Research Center, Department of Biomedical Sciences, College of Medicine, Seoul National University) ;
  • Soung, Nak-Kyun (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Kim, Bo Yeon (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
  • Received : 2019.02.25
  • Accepted : 2019.04.09
  • Published : 2019.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Methylation is a primary epigenetic mechanism regulating gene expression. 5-aza-2'-deoxycytidine is an FDA-approved drug prescribed for treatment of cancer by inhibiting DNA-Methyl-Transferase 1 (DNMT1). Results of this study suggest that prolonged treatment with 5-aza-2'-deoxycytidine could induce centrosome abnormalities in cancer cells and that CEP131, a centrosome protein, is regulated by DNMT1. Interestingly, cancer cell growth was attenuated in vitro and in vivo by inhibiting the expression of Cep131. Finally, Cep131-deficient cells were more sensitive to treatment with DNMT1 inhibitors. These findings suggest that Cep131 is a potential novel anti-cancer target. Agents that can inhibit this protein may be useful alone or in combination with DNMT1 inhibitors to treat cancer.

Keywords

References

  1. Yen RW, Vertino PM, Nelkin BD et al (1992) Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res 20, 2287-2291 https://doi.org/10.1093/nar/20.9.2287
  2. Guntaka RV, Gowda S, Wagner H and Simon D (1987) Methylation of the enhancer region of avian sarcoma virus long terminal repeat suppresses transcription. FEBS Lett 221, 332-336 https://doi.org/10.1016/0014-5793(87)80951-1
  3. Kwon YW, Ahn HS, Park JY, Yang HM, Cho HJ, Kim HS (2018) Imprinted gene Zinc finger protein 127 is a novel regulator of master pluripotency transcription factor, Oct4. BMB Rep 51, 242-248 https://doi.org/10.5483/BMBRep.2018.51.5.196
  4. Jair KW, Bachman KE, Suzuki H et al (2006) De novo CpG island methylation in human cancer cells. Cancer Res 66, 682-692 https://doi.org/10.1158/0008-5472.CAN-05-1980
  5. Ting AH, Jair KW, Schuebel KE and Baylin SB (2006) Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res 66, 729-735 https://doi.org/10.1158/0008-5472.CAN-05-1537
  6. Song MH, Nair VS, Oh KI (2017) Vitamin C enhances the expression of IL17 in a Jmjd2-dependent manner. BMB Rep 50, 49-54 https://doi.org/10.5483/BMBRep.2017.50.1.193
  7. Zhang X, Yashiro M, Ohira M, Ren J and Hirakawa K (2006) Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci 97, 938-944 https://doi.org/10.1111/j.1349-7006.2006.00253.x
  8. Schafer PW (1969) Centrioles of a human cancer: intercellular order and intracellular disorder. Science 164, 1300-1303 https://doi.org/10.1126/science.164.3885.1300
  9. Lingle WL, Lutz WH, Ingle JN, Maihle NJ and Salisbury JL (1998) Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A 95, 2950-2955 https://doi.org/10.1073/pnas.95.6.2950
  10. Salisbury JL, Whitehead CM, Lingle WL and Barrett SL (1999) Centrosomes and cancer. Biol Cell 91, 451-460 https://doi.org/10.1111/j.1768-322X.1999.tb01100.x
  11. Meador JA, Su Y, Ravanat JL and Balajee AS (2010) DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine. Carcinogenesis 31, 184-191 https://doi.org/10.1093/carcin/bgp284
  12. Kramer A, Neben K and Ho AD (2002) Centrosome replication, genomic instability and cancer. Leukemia 16, 767-775 https://doi.org/10.1038/sj.leu.2402454
  13. Lingle WL, Barrett SL, Negron VC et al (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A 99, 1978-1983 https://doi.org/10.1073/pnas.032479999
  14. Liu XH, Yang YF, Fang HY, Wang XH, Zhang MF and Wu DC (2017) CEP131 indicates poor prognosis and promotes cell proliferation and migration in hepatocellular carcinoma. Int J Biochem Cell Biol 90, 1-8 https://doi.org/10.1016/j.biocel.2017.07.001
  15. Li X, Song N, Liu L et al (2017) USP9X regulates centrosome duplication and promotes breast carcinogenesis. Nat Commun 8, 14866 https://doi.org/10.1038/ncomms14866
  16. Barra V, Schillaci T, Lentini L, Costa G and Di Leonardo A (2012) Bypass of cell cycle arrest induced by transient DNMT1 post-transcriptional silencing triggers aneuploidy in human cells. Cell Div 7, 2 https://doi.org/10.1186/1747-1028-7-2
  17. Chen T, Hevi S, Gay F et al (2007) Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet 39, 391-396 https://doi.org/10.1038/ng1982
  18. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837 https://doi.org/10.1038/sj.onc.1207528
  19. Damelin M and Bestor TH (2007) Biological functions of DNA methyltransferase 1 require its methyltransferase activity. Mol Cell Biol 27, 3891-3899 https://doi.org/10.1128/MCB.00036-07
  20. Lee B and Muller MT (2009) SUMOylation enhances DNA methyltransferase 1 activity. Biochem J 421, 449-461 https://doi.org/10.1042/BJ20090142
  21. Robert MF, Morin S, Beaulieu N et al (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33, 61-65 https://doi.org/10.1038/ng1068
  22. Li LC and Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427-1431 https://doi.org/10.1093/bioinformatics/18.11.1427
  23. Bock C, Reither S, Mikeska T, Paulsen M, Walter J and Lengauer T (2005) BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 21, 4067-4068 https://doi.org/10.1093/bioinformatics/bti652
  24. Huong PT, Soung NK, Jang JH et al (2013) Regulation of CEP131 gene expression by SP1. Gene 513, 75-81 https://doi.org/10.1016/j.gene.2012.10.074
  25. Milutinovic S, Brown SE, Zhuang Q and Szyf M (2004) DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J Biol Chem 279, 27915-27927 https://doi.org/10.1074/jbc.M312823200
  26. Tian HP, Lun SM, Huang HJ et al (2015) DNA methylation affects the SP1-regulated transcription of FOXF2 in breast cancer cells. J Biol Chem 290, 19173-19183 https://doi.org/10.1074/jbc.M114.636126
  27. Zhao W, Song Y, Xu B and Zhan Q (2012) Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel. Cancer Biol Ther 13, 156-163 https://doi.org/10.4161/cbt.13.3.18697
  28. Loffler H, Fechter A, Matuszewska M et al (2011) Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance. Cancer Res 71, 2129-2139 https://doi.org/10.1158/0008-5472.CAN-10-2684
  29. Li JJ and Li SA (2006) Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 111, 974-984 https://doi.org/10.1016/j.pharmthera.2006.02.006
  30. Staples CJ, Myers KN, Beveridge RD et al (2012) The centriolar satellite protein Cep131 is important for genome stability. J Cell Sci 125, 4770-4779 https://doi.org/10.1242/jcs.104059
  31. Hall EA, Keighren M, Ford MJ et al (2013) Acute versus chronic loss of mammalian Azi1/Cep131 results in distinct ciliary phenotypes. PLoS Genet 9, e1003928 https://doi.org/10.1371/journal.pgen.1003928
  32. Jung Y, Park J, Kim TY et al (2007) Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med (Berl) 85, 1137-1148 https://doi.org/10.1007/s00109-007-0216-z
  33. Yuan L, Chan GC, Fung KL and Chim CS (2014) RANKL expression in myeloma cells is regulated by a network involving RANKL promoter methylation, DNMT1, microRNA and TNFalpha in the microenvironment. Biochim Biophys Acta 1843, 1834-1838 https://doi.org/10.1016/j.bbamcr.2014.05.010
  34. Wilkinson CJ, Carl M and Harris WA (2009) Cep70 and Cep131 contribute to ciliogenesis in zebrafish embryos. BMC Cell Biol 10, 17 https://doi.org/10.1186/1471-2121-10-17
  35. Buchi F, Spinelli E, Masala E et al (2012) Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res 36, 607-618 https://doi.org/10.1016/j.leukres.2011.11.024
  36. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264 https://doi.org/10.1038/nrc3239
  37. Weintraub K (2016) Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med 22, 8-10 https://doi.org/10.1038/nm0116-8